Retatrutide has not yet been approved for any form of human use; however, it is available to qualified researchers for studying its therapeutic potential as a triple receptor agonist.
Retatrutide is currently undergoing clinical development within Eli Lilly’s TRIUMPH phase-3 clinical program, which aims to gather extensive data on its efficacy and safety. This program is designed to provide comprehensive insights that could eventually support regulatory approval for medical use.
However, data from phase 1 and phase 2 trials suggest that the peptide is generally well-tolerated, with side effects similar to those observed with FDA-approved incretin mimetics such as dulaglutide, indicating a comparable safety profile.
Nevertheless, researchers using retatrutide in laboratory settings must remain mindful of potential risks, ensuring that all handling and experimentation are conducted under strict professional supervision.
Is Retatrutide Legal?
Retatrutide is not currently available as a prescription medication and has not been approved for human use in the United States or internationally. As of this writing, it remains under investigation in clinical trials for potential applications in treating conditions like type 2 diabetes and obesity, similar to other incretin mimetics.
Qualified researchers and laboratory professionals can legally obtain retatrutide as a reference material for research purposes. However, it is important to note that retatrutide is not available over-the-counter and cannot be used as a dietary supplement.
Unqualified use of retatrutide could lead to legal repercussions, and improper administration carries significant health risks. Researchers should avoid purchasing retatrutide marketed as a supplement or included as an ingredient in supplements, as such products are often of low quality and may pose serious dangers to research subjects.
Retatrutide Dosing | Research Only
Researchers are advised to follow specific dosing protocols to ensure the safety and efficacy of retatrutide in weight loss studies. The dosing regimen starts with a low dose of 1 mg per week, which is gradually increased to minimize side effects. The recommended schedule is as follows:
- Weeks 1-4: Start with 1 mg weekly
- Weeks 5-8: Increase to 2 mg weekly
- Weeks 9-12: Increase to 4 mg weekly
- Weeks 13-16: Increase to 8 mg weekly
- Week 17+: Reach the full dose of 12 mg weekly
It’s essential that researchers do not exceed the maximum recommended dosage of 12 mg per week. Retatrutide is designed for once-weekly subcutaneous administration, and due to its extended half-life, it can be injected at any time of day, with or without food [6,7].
In clinical trials, the preferred injection site has been the abdomen, specifically at least 2 inches (5 cm) away from the belly button, to minimize the risk of bruising, redness, infection, or irritation. Studies have shown that retatrutide can be safely administered over a 48-week period, with a safety profile comparable to that of a placebo and other incretin mimetics [6,7].
This long-term dosing approach indicates that retatrutide does not require cycling on and off, and sustained use is crucial for maximizing its therapeutic effects in weight management and metabolic health improvement.
